Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00228527 · ClinicalTrials.gov registry record · Phase 4
Esomeprazole for Treatment of GERD in Pediatric Patients
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT00228527 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 100 participants.
The verdict
NCT00228527, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
To look at the safety and improvement in symptoms of a once a day dosing of esomeprazole in children 1 to 11 years old with inflammation of their esophagus or food pipe ("esophagitis") caused by gastroesophageal reflux disease (GERD) and diagnosed by endoscopy. To verify the healing of the esophageal inflammation if the endoscopy reveals cuts in the lining of the food pipe. To collect information that will describe the psychological, social, and economic effects on the primary caregiver of raising children ages 1 to 5 years old with GERD.
Interventions
- DRUG Esomeprazole (Nexium)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2004-10 |
| Est. Completion | 2005-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00228527
The ClinicalTrials.gov registry entry for NCT00228527 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Esomeprazole (Nexium) is the first listed.
NCT00228527 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00228527 about?
NCT00228527 is a clinical study titled "Esomeprazole for Treatment of GERD in Pediatric Patients". To look at the safety and improvement in symptoms of a once a day dosing of esomeprazole in children 1 to 11 years old with inflammation of their esophagus or food pipe ("esophagitis") caused by gastroesophageal reflux disease (GERD) and diagnosed by endoscopy. To verify the healing of the esophage...
What is the current status of trial NCT00228527?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2004-10. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00228527?
The interventions under investigation include: Esomeprazole (Nexium) (DRUG).
Who is sponsoring clinical trial NCT00228527?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.